Global HP (High Potency) APIs Market Report 2021: Market is Expected to Reach $27.3 Billion in 2025 at a CAGR of 7.7% with Long-term Forecast to 2030 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "HP (High Potency) APIs Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com's offering.

The global HP (High Potency) APIs market is expected to grow from $19.27 billion in 2020 to $20.3 billion in 2021 at a compound annual growth rate (CAGR) of 5.3%. The market is expected to reach $27.3 billion in 2025 at a CAGR of 7.7%.

Major players in the HP (High Potency) APIs market are Eli Lily and Company, Novartis AG, Bristol-Myers Squibb Company, Roche Diagnostics Ltd., Sanofi, Hospira Inc., BASF SE, Covidien plc, Boehringer Ingelheim GmbH and Merck & Co. Inc.

The high potency APIs (HPAPI) market consists of sales of high potency active pharmaceutical ingredients and related services. High potency APIs are extremely effective in pharmacologically active ingredients. These are highly specific in their action and offer significant efficiency even at the low daily therapeutic doses. HPAPIs are used in formulations for high potent drugs, owing to their ability to target precise disease cells including cancer cells.

High investment requirements are anticipated to restrain the growth of the market over the coming years. The high potency APIs are cytotoxic, which are harmful to human cells. Moreover, they carry significant handling challenges including the requirement for specialized equipment to avoid cross-contamination, product protection, and to ensure environment and operator safety.

Additionally, the requirement for appropriate process design and the constant evolution of technologies and industry standards, specialized containment facilities to facilitate the safety of the employees requires huge financial support. Therefore, large investment requirement acts as a major challenge for the growth of the high potency APIs market.

The rising number of cancer cases coupled with increasing sales of cancer drugs contributed to the growth of the high potency APIs market. Rising incidence of cancer is resulting in increasing R&D about anticancer drugs which in turn is propelling the demand for high potency APIs market. Therefore, the growing incidence of cancer cases is projected to upsurge revenues for the high potency APIs market.

The companies dealing in the high potency APIs market are focusing on strategies such as production facility expansion and mergers & acquisitions to maintain their position in the competitive business environment.

Key Topics Covered:

1. Executive Summary

2. HP (High Potency) APIs Market Characteristics

3. HP (High Potency) APIs Market Trends and Strategies

4. Impact Of COVID-19 On HP (High Potency) APIs

5. HP (High Potency) APIs Market Size and Growth

5.1. Global HP (High Potency) APIs Historic Market, 2015-2020, $ Billion

5.1.1. Drivers Of the Market

5.1.2. Restraints On the Market

5.2. Global HP (High Potency) APIs Forecast Market, 2020-2025F, 2030F, $ Billion

5.2.1. Drivers Of the Market

5.2.2. Restraints On the Market

6. HP (High Potency) APIs Market Segmentation

6.1. Global HP (High Potency) APIs Market, Segmentation by Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

• Innovative HPAPI
• Generic HPAPI

6.2. Global HP (High Potency) APIs Market, Segmentation by Synthesis Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

• Synthetic HPAPI
• Biotech HPAPI

6.3. Global HP (High Potency) APIs Market, Segmentation by therapeutic Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

• Oncology
• Hormonal Disorder
• Glaucoma
• Other therapeutic Applications (Respiratory Disorders, CVD, Diabetes, Cosmetology, and Erectile Dysfunction)

7. HP (High Potency) APIs Market Regional and Country Analysis

7.1. Global HP (High Potency) APIs Market, Split by Region, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

7.2. Global HP (High Potency) APIs Market, Split by Country, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

Companies Mentioned

• Eli Lily and Company
• Novartis AG
• Bristol-Myers Squibb Company
• Roche Diagnostics Ltd.
• Sanofi
• Hospira Inc.
• BASF SE
• Covidien plc
• Boehringer Ingelheim GmbH
• Merck & Co. Inc.
• Sigma Aldrich Corporation
• Bayer AG
• Carbogen Amcis AG
• Lonza
• Teva Pharmaceutical Industries Ltd.
• Pfizer Inc.
• Mylan Inc.
• AbbVie
• AstraZeneca plc
• GlaxoSmithKline PLC

For more information about this report visit https://www.researchandmarkets.com/r/rale4a

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900